Welcome Mattias!
From March 4, Mattias Bergentall joins the MetaboGen team as our new microbiologist. We welcome Mattias and look forward to continuing ou (...) Read the full story
News
Latest news from Metabogen
We are hiring!
MetaboGen is growing and we are now looking for a Microbiologist and a Project Manager to join our development team. Read more about the (...) Read the full story
MetaboGen reaches development goal – first product ready for safety study
BioGaia today announced that its´ subsidiary MetaboGen has reached an important development goal. The first version of its next generati (...) Read the full story
Fredrik Bäckhed får prestigefyllt pris på EASD
MetaboGens medgrundare Fredrik Bäckhed har tilldelats the Minkowski Award på EASD.
– Det är väldigt hedrande att få det hä (...) Read the full story
BioGaia invests further in MetaboGen
On April 6, 2018, BioGaia became the majority shareholder in MetaboGen with a
62 percent stake. BioGaia has now, after the set mile (...) Read the full story
BioGaia continues to invest in MetaboGen
On April 6 2018, BioGaia announced its decision to acquire additional shares in MetaboGen and is now investing SEK 11.7 million in shares (...) Read the full story
MetaboGen is granted US diabetes patent
MetaboGen AB has on January 30th, 2018 been granted a US patent for the identification of a person at risk for developing type 2 diabetes (...) Read the full story
Gravid med erfarenhet av graviditetsklåda?
Just nu pågår en forskningsstudie i Skåne och Stockholm för att undersöka bakgrunden till graviditetsklåda och om bakteriefloran i (...) Read the full story
MetaboGen and BioGaia initiates program for microbiome restoration
Today, MetaboGen and BioGaia have agreed to initiate a new development program addressing restoration of the microbiome after antibiotic (...) Read the full story
Jens Nielsen on the list of the world´s most-cited scientists
Web of Science has just published its list of the world’s most-cited researchers. The list includes, for the third year in a row, Metab (...) Read the full story